Floatz logo

Tirzepatide

Cannabis Use Disorder, Moderate

McMaster Universityprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Cannabis Use Disorder, Moderate cohort.

Asset / SponsorPhaseRating
Clozapine
Dartmouth-Hitchcock Medical Center
Phase 4BB
Risperdal
Dartmouth-Hitchcock Medical Center
Phase 4BB
Topamax
University of Cincinnati
Phase 4BB
Seroquel®
University of Cincinnati
Phase 4BB
Metformin
Nova Scotia Health Authority
Phase 4BB

View all 15 →

Same molecule, other indications

Tirzepatide is also rated in:

type 1 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
psoriatic arthritisDormant
BBB
Indicative ·
74 / 100
View asset →
diastolic heart failureDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →